ZA202305622B - Free base crystalline form of a complement component c5a receptor - Google Patents
Free base crystalline form of a complement component c5a receptorInfo
- Publication number
- ZA202305622B ZA202305622B ZA2023/05622A ZA202305622A ZA202305622B ZA 202305622 B ZA202305622 B ZA 202305622B ZA 2023/05622 A ZA2023/05622 A ZA 2023/05622A ZA 202305622 A ZA202305622 A ZA 202305622A ZA 202305622 B ZA202305622 B ZA 202305622B
- Authority
- ZA
- South Africa
- Prior art keywords
- free base
- receptor
- crystalline form
- complement component
- base crystalline
- Prior art date
Links
- 239000012458 free base Substances 0.000 title abstract 3
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 title 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 title 1
- 230000000295 complement effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010078546 Complement C5a Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932652P | 2019-11-08 | 2019-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202305622B true ZA202305622B (en) | 2024-01-31 |
Family
ID=75846182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/05622A ZA202305622B (en) | 2019-11-08 | 2023-05-25 | Free base crystalline form of a complement component c5a receptor |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11026935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054577A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554019A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220098179A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114641289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020378061A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007488A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155596A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001173A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292317A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005403A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021092292A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202305622B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| JP5819730B2 (ja) * | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) * | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| AU2020380367B2 (en) * | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 AU AU2020378061A patent/AU2020378061A1/en not_active Abandoned
- 2020-11-06 BR BR112022007488A patent/BR112022007488A2/pt not_active IP Right Cessation
- 2020-11-06 KR KR1020227018961A patent/KR20220098179A/ko not_active Withdrawn
- 2020-11-06 IL IL292317A patent/IL292317A/en unknown
- 2020-11-06 CA CA3155596A patent/CA3155596A1/en active Pending
- 2020-11-06 US US17/091,019 patent/US11026935B2/en active Active
- 2020-11-06 JP JP2022525889A patent/JP2022554019A/ja not_active Withdrawn
- 2020-11-06 CN CN202080077446.8A patent/CN114641289A/zh active Pending
- 2020-11-06 MX MX2022005403A patent/MX2022005403A/es unknown
- 2020-11-06 EP EP20884944.8A patent/EP4054577A4/en not_active Withdrawn
- 2020-11-06 WO PCT/US2020/059287 patent/WO2021092292A1/en not_active Ceased
-
2021
- 2021-05-04 US US17/307,865 patent/US20220096453A1/en not_active Abandoned
-
2022
- 2022-05-04 CL CL2022001173A patent/CL2022001173A1/es unknown
-
2023
- 2023-04-24 US US18/305,611 patent/US20230381167A1/en not_active Abandoned
- 2023-05-25 ZA ZA2023/05622A patent/ZA202305622B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292317A (en) | 2022-06-01 |
| CL2022001173A1 (es) | 2023-02-10 |
| EP4054577A1 (en) | 2022-09-14 |
| MX2022005403A (es) | 2022-05-24 |
| BR112022007488A2 (pt) | 2022-07-12 |
| CN114641289A (zh) | 2022-06-17 |
| JP2022554019A (ja) | 2022-12-27 |
| CA3155596A1 (en) | 2021-05-14 |
| WO2021092292A1 (en) | 2021-05-14 |
| EP4054577A4 (en) | 2023-11-29 |
| US20220096453A1 (en) | 2022-03-31 |
| KR20220098179A (ko) | 2022-07-11 |
| AU2020378061A1 (en) | 2022-05-26 |
| US20210137907A1 (en) | 2021-05-13 |
| US20230381167A1 (en) | 2023-11-30 |
| US11026935B2 (en) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005403A (es) | Forma cristalina de base libre de un receptor del componente c5a de complemento. | |
| ZA202305624B (en) | Amorphous form of a complement component c5a receptor | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| PH12020551821A1 (en) | Novel compounds | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| MX2024009540A (es) | Esteroides neuroactivos y composiciones de estos. | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| ZA202204442B (en) | Salt forms of a complement component c5a receptor | |
| CR20200116A (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2024015245A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2020008982A (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. | |
| MX2025011614A (es) | Forma cristalina de un antagonista de ep4 | |
| WO2020049598A3 (en) | Apalutamide polymorphs |